Parhelia Biosciences

Executive Summary

Parhelia Biosciences is a San Diego-based biotechnology company focused on advancing spatial biology through automation. Its flagship product, the Spatial Station, is a benchtop instrument that automates complex multi-step sample preparation for high-plex tissue analysis, including multiplexed immunofluorescence, in situ hybridization, and CODEX/PCF assays. By improving reproducibility, reducing reagent waste, and freeing up researcher time, Parhelia addresses a critical bottleneck in spatial biology workflows, enabling more consistent and scalable tissue analysis. Founded in 2018, the company targets the rapidly growing spatial biology market, driven by increasing demand for spatially resolved omics in oncology and diagnostics research. With its commercial-grade platform, Parhelia is well-positioned to capture a share of the automated instrumentation market as labs transition from manual protocols to standardized, high-throughput solutions. The company's focus on benchtop accessibility and workflow integration differentiates it from larger, more capital-intensive systems, potentially appealing to core facilities and academic labs seeking cost-effective automation.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation consumables for Spatial Station70% success
• Q2 2027Strategic partnership with a leading pharmaceutical company for spatial profiling50% success
• Q3 2026Series B funding round to scale manufacturing and sales60% success